{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-009622","form_type":"8-K","ticker":"MBIO","cik":"0001680048","company_name":"MUSTANG BIO, INC.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.009959+00:00","generated_at":"2026-06-15T02:37:23.518340+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Mustang Bio Q1 net loss $16.7M, cash $58.8M; MB-106 trial data expected Q2","bullets":["Cash and cash equivalents $58.8M at Mar 31, 2023, down $17.9M from Dec 31, 2022.","Net loss $16.7M ($2.06/share) vs $19.8M ($2.71/share) in Q1 2022; R&D expenses $14.0M.","MB-106 (CD20 CAR T) shows 96% ORR and 75% CR in Fred Hutch trial; multicenter trial accruing.","Orphan Drug Designation for MB-106 in Waldenstrom macroglobulinemia; pivotal Phase 2 may start Q1 2024.","In April 2023, executed 15-for-1 reverse stock split and repaid $30.7M loan to Runway."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-009622","json":"https://secwatch.observer/filing/0001558370-23-009622.json","markdown":"https://secwatch.observer/filing/0001558370-23-009622.md","text":"https://secwatch.observer/filing/0001558370-23-009622.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680048/000155837023009622/0001558370-23-009622-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680048/000155837023009622/tmb-20230512x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:37:23.518340+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"88209729768f51e51efccf331dc05b021ad292b8","claim":"MUSTANG BIO, INC. reported the first quarter ended March 31, 2023 results: net income Net loss attributable to common stockholders was $16.7 million, or $2.06 per share.","evidence_excerpt":"On May 12, 2023, Mustang Bio, Inc. issued a press release to provide a corporate update and to announce its financial results for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680048/000155837023009622/0001558370-23-009622-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss attributable to common stockholders was $16.7 million, or $2.06 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}